Merck Misled USPTO In Singulair Patent Case: Teva

Law360, New York (September 9, 2008, 12:00 AM EDT) -- Generic-drug maker Teva Pharmaceuticals USA Inc. on Monday sought to compel Merck & Co. Inc. to divulge what Teva alleges is prior art information that could undermine a patent for the best-selling allergy drug Singulair.

Merck's Barbados-based affiliate, Merck Sharp & Dohme Pharmaceuticals SRL, sued Teva in April 2007 in the U.S. District Court for the District of New Jersey, claiming Teva's abbreviated new drug application with the U.S. Food and Drug Administration for a generic version of Singulair violates its patent.

The complaint claims Teva...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.